Blay JY - Search Results

1

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.

Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY; Groupe Francais d'Immunotherapie. Negrier S, et al. Among authors: blay jy. J Clin Oncol. 2004 Jun 15;22(12):2371-8. doi: 10.1200/JCO.2004.06.121. J Clin Oncol. 2004. PMID: 15197198

2

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

Blay JY, Négrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, Philip T, Favrot M. Blay JY, et al. Bull Cancer. 1992;79(1):55-65. Bull Cancer. 1992. PMID: 1520953 French.

3

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

Négrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel M, et al. Négrier S, et al. Among authors: blay jy. Br J Cancer. 1992 May;65(5):723-6. doi: 10.1038/bjc.1992.152. Br J Cancer. 1992. PMID: 1586600 Free PMC article. Clinical Trial.

4

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al. Blay JY, et al. Cancer Res. 1992 Jun 15;52(12):3317-22. Cancer Res. 1992. PMID: 1596890

5

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T. Blay JY, et al. Cancer Res. 1990 Apr 15;50(8):2371-4. Cancer Res. 1990. PMID: 2317822

6

The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report.

Carrie C, Breteau N, Negrier S, Frappaz D, Bouffet E, Thiesse P, Blay JY, Clavel M, Philip T, Biron P, et al. Carrie C, et al. Among authors: blay jy. Med Pediatr Oncol. 1994;22(5):355-7. doi: 10.1002/mpo.2950220512. Med Pediatr Oncol. 1994. PMID: 8127261

7

Medulloblastoma in adults: survival and prognostic factors.

Carrie C, Lasset C, Blay JY, Négrier S, Bouffet E, Barbet N, Montbarbon X, Wagner JP, Lapras C, Deruty R, et al. Carrie C, et al. Among authors: blay jy. Radiother Oncol. 1993 Dec;29(3):301-7. doi: 10.1016/0167-8140(93)90148-2. Radiother Oncol. 1993. PMID: 8127980

8

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

Ravaud A, Négrier S, Cany L, Merrouche Y, Le Guillou M, Blay JY, Clavel M, Gaston R, Oskam R, Philip T. Ravaud A, et al. Among authors: blay jy. Br J Cancer. 1994 Jun;69(6):1111-4. doi: 10.1038/bjc.1994.218. Br J Cancer. 1994. PMID: 8198979 Free PMC article. Clinical Trial.

9

[Treatment with cytokines of metastatic kidney cancer: the Lyon experience].

Négrier S, Mercatello A, Coronel B, Lanier F, Merrouche Y, Bret M, Blay JY, Lasset C, Thiesse P, Carrie C, et al. Négrier S, et al. Among authors: blay jy. Bull Cancer. 1993 Jul;80(7):601-9. Bull Cancer. 1993. PMID: 8204940 Clinical Trial. French.

10

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

Philip T, Negrier S, Lasset C, Coronel B, Bret M, Blay JY, Merrouche Y, Carrie C, Kaemmerlen P, Chauvin F, et al. Philip T, et al. Among authors: blay jy. Br J Cancer. 1993 Nov;68(5):1036-42. doi: 10.1038/bjc.1993.476. Br J Cancer. 1993. PMID: 8217594 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,003 results

Search Page